BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Annual Shareholder Letter Provides Company Highlights, 2022 Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, has released a shareholder letter. The letter, from president and CEO Eric A. Adams, provided INM shareholders with a company update, including a look at key milestones the company had reached, including the acquisition of BayMedica, which Adams said positioned InMed as a clear leader in rare cannabinoid manufacturing. Adams also noted that the company continued to make significant strides with its proprietary IntegraSyn(TM) program and is advancing its pharmaceutical programs, thanks in large part to the library of novel cannabinoid analogs developed by BayMedica. The company also initiated a phase 2 trial of its INM-755 program for the treatment of epidermolysis bullosa (“EB”) and remained focused on advancing its INM-088 program for the treatment of glaucoma toward human clinical trials. In addition, Adams noted that the company is evaluating promising new research the use of a rare cannabinoid as a potential treatment option for neurodegenerative diseases. Financially, INM funded operations through the completion of two financings. Adams also announced an upcoming webinar, slated for Thursday, Jan. 6, 2022, during which the company’s management team will discuss the increasing demand for rare cannabinoids as well as plans for 2022. “Following the acquisition of BayMedica, our primary and immediate focus is completing the integration of the two companies and expediting commercial activities,” said InMed president and CEO Eric A. Adams in the letter. “We look forward to launching several new nonintoxicating rare cannabinoids in early 2022, including CBDV and THCV, two high-demand products in the consumer health and wellness sector, and envisage significant revenue growth over the coming quarters. Our unparalleled capabilities and expertise in cannabinoid manufacturing positions us as a leader in this burgeoning segment of the industry and sets us apart from our competitors.”

To view the webinar, visit https://ibn.fm/g9egQ

To view the full press release, visit https://ibn.fm/FTbSh  

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork